10 research outputs found

    5HT2A Receptor Antagonist Treatment for Repetitive Behaviors and Restricted Interests in BTBR Mice

    No full text
    Individuals with autism spectrum disorder (ASD) commonly exhibit an “insistence on sameness” which is characterized by a compulsive adherence to a thought pattern or stereotyped behavior. Insistence on sameness in ASD can result in behavioral flexibility deficits when a situation requires a shift in thought patterns or actions. To date, there lacks effective treatments to alleviate insistence on sameness features, which is in part due to the limited knowledge about the underlying neuropathophysiology contributing to behavioral inflexibility and stereotyped behavior. This project investigated whether pharmacologically targeting 5HT2A receptors in an idiopathic model of ASD, the BTBR mouse, affects the expression of a phenotype that is related to RRBs in ASD. The findings suggest that altered 5HT2A receptor signaling in BTBR mice may contribute to behavioral flexibility deficits and elevated grooming which can be attenuated by systemic treatment with a 5HT2A receptor antagonist. A behavioral flexibility deficit observed in BTBR mice may result, in part, from increased 5HT2A receptor signaling in the dorsomedial striatum. In contrast, 5HT2A receptor signaling in the orbitofrontal cortex may be normal in BTBR mice, but when 5HT2A receptor blockade of this region leads to perseveration of both cognitive and stereotyped behaviors. Overall, these findings suggest that 5HT2A receptor antagonist treatment may be effective in ameliorating RRBs in ASD, in part, by correcting altered 5HT2A receptor signaling in the striatum

    Oxotremorine treatment reduces repetitive behaviors in BTBR T+ tf/J mice

    Get PDF
    Repetitive behaviors with restricted interests is one of the core criteria for the diagnosis of autism spectrum disorder (ASD). Current pharmacotherapies that target the dopaminergic or serotonergic systems have limited effectiveness in treating repetitive behaviors. Previous research has demonstrated that administration of muscarinic cholinergic receptor (mAChR) antagonists can exacerbate motor stereotypies while mAChR agonists reduce stereotypies. The present study determined whether the mAChR agonist, oxotremorine affected repetitive behaviors in the BTBR T+ tf/J (BTBR) mouse model of autism. To test the effects of oxotremorine on repetitive behaviors, marble burying and grooming behavior were measured in BTBR mice and compared to that in C57BL/6J (B6) mice. The effects of oxotremorine on locomotor activity was also measured. Thirty minutes before each test, mice received an intraperitoneal injection of saline, 0.001mg or 0.01mg of oxotremorine methiodide. Saline treated BTBR mice exhibited increased marble burying and self-grooming behavior compared to that of saline-treated B6 mice. Oxotremorine significantly reduced marble burying and self48 grooming behavior in BTBR mice, but had no significant effect in B6 mice. In addition, oxotremorine did not affect locomotor activity in BTBR mice, but significantly reduced locomotor activity in B6 mice at the 0.01mg dose. These findings demonstrate that activation of mAChRs reduces repetitive behavior in the BTBR mouse and suggest that treatment with a mAChR agonist may be effective in reducing repetitive behaviors in ASD
    corecore